{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:52:24Z","timestamp":1791604344058,"version":"4.3.4"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,3,1]],"date-time":"2027-03-01T00:00:00Z","timestamp":1803859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2027,3]]},"DOI":"10.1016\/j.vhri.2026.102132","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:24:56Z","timestamp":1791602696000},"page":"102132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["What Strategies Can Payers Use to Negotiate Medicine Prices Globally? Insights and Lessons for Low-Income Countries from a Scoping Review"],"prefix":"10.1016","volume":"58","author":[{"given":"Lan","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.vhri.2026.102132_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vhri.2026.102132_bib3","series-title":"Global Spending on Health: Rising to the Pandemic\u2019s Challenges","year":"2022"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.vhri.2026.102132_bib5","series-title":"Primary health care on the road to universal health coverage","year":"2019"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.healthpol.2011.09.003","article-title":"The effects of new pricing and copayment schemes for pharmaceuticals in South Korea","volume":"104","author":"Lee","year":"2012","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"10.1016\/j.vhri.2026.102132_bib7","series-title":"Non communicable diseases","year":"2024"},{"issue":"10","key":"10.1016\/j.vhri.2026.102132_bib8","article-title":"Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies","volume":"2014","author":"Acosta","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11537860-000000000-00000","article-title":"Effects of reference pricing in pharmaceutical markets: a review","volume":"29","author":"Galizzi","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.102132_bib10","series-title":"WHO Guideline on Country Pharmaceutical Pricing Policies","article-title":"Systematic reviews for the update of the WHO Guideline on country pharmaceutical pricing policies","author":"Tordrup","year":"2020"},{"issue":"10067","key":"10.1016\/j.vhri.2026.102132_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(16)31599-9","article-title":"Essential medicines for universal health coverage","volume":"389","author":"Wirtz","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jphs.12191","article-title":"A systematic review of pharmaceutical pricing policies in developing countries","volume":"8","author":"Abdel Rida","year":"2017","journal-title":"J Pharm Health Serv Res"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1377\/hlthaff.27.1.221","article-title":"International prices and availability of pharmaceuticals in 2005","volume":"27","author":"Danzon","year":"2008","journal-title":"Health Aff (Millwood)"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.gaceta.2009.12.003","article-title":"Policies encouraging price competition in the generic drug market: lessons from the European experience","volume":"24","author":"Puig-Junoy","year":"2010","journal-title":"Gac Sanit"},{"issue":"8","key":"10.1016\/j.vhri.2026.102132_bib15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/11535360-000000000-00000","article-title":"Impact of European pharmaceutical price regulation on generic price competition: a review","volume":"28","author":"Puig-Junoy","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"2-3","key":"10.1016\/j.vhri.2026.102132_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.healthpol.2010.10.020","article-title":"Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: a systematic review of current evidence","volume":"100","author":"Faden","year":"2011","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1812959","article-title":"Brazil\u2019s fight against hepatitis C\u2014universalism, local production, and patents","volume":"380","author":"da Fonseca","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vhri.2026.102132_bib20","series-title":"The Joanna Briggs Institute Reviewers\u2019 Manual 2015","article-title":"Methodology for JBI scoping reviews","author":"Peters","year":"2015"},{"key":"10.1016\/j.vhri.2026.102132_bib21","series-title":"Scoping Reviews: Chapter 11. 2020 version","article-title":"JBI Manual for evidence synthesis","author":"Peters","year":"2020"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vhri.2026.102132_bib23","series-title":"World bank country and lending groups","year":"2026"},{"issue":"9","key":"10.1016\/j.vhri.2026.102132_bib24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jval.2023.05.018","article-title":"Incorporating added therapeutic benefit and domestic reference pricing into Medicare payment for expensive part B drugs","volume":"26","author":"Anderson","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-012-0002-9","article-title":"Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?","volume":"31","author":"Gandjour","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.vhri.2026.102132_bib26","first-page":"e429","article-title":"A systematic review of reference pricing: implications for US prescription drug spending","volume":"18","author":"Lee","year":"2012","journal-title":"Am J Manag Care"},{"issue":"12","key":"10.1016\/j.vhri.2026.102132_bib27","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1111\/poms.13246","article-title":"External reference pricing and parallel imports of pharmaceuticals: a policy comparison","volume":"29","author":"Iravani","year":"2020","journal-title":"Prod Oper Manag"},{"issue":"6","key":"10.1016\/j.vhri.2026.102132_bib28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/14737167.2013.847367","article-title":"Differential pricing of new pharmaceuticals in lower income European countries","volume":"13","author":"Kal\u00f3","year":"2013","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1025384819575","article-title":"Differential pricing for pharmaceuticals: reconciling access, R&D and patents","volume":"3","author":"Danzon","year":"2003","journal-title":"Int J Health Care Finance Econ"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/1741134320963146","article-title":"COVID-19 and the global public health: tiered pricing of pharmaceutical drugs as a price-reducing policy tool","volume":"17","author":"Abbas","year":"2021","journal-title":"J Generic Med"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12913-020-5055-4","article-title":"A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency","volume":"20","author":"Gandjour","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/14737167.2014.868313","article-title":"Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor","volume":"14","author":"Gandjour","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2026.102132_bib33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.vhri.2018.09.007","article-title":"Value-based pricing in Latin America: how far away are we?","volume":"17","author":"Mejia","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vhri.2019.11.008","article-title":"International experience in therapeutic value and value-based pricing: a rapid review of the literature","volume":"23","author":"Prieto-Pinto","year":"2020","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14737167.2018.1497976","article-title":"The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?","volume":"18","author":"Sandmann","year":"2018","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.healthpol.2021.12.007","article-title":"How value-based policy interventions influence price negotiations for new medicines: an experimental approach and initial evidence","volume":"126","author":"Wettstein","year":"2022","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/14737167.2023.2283584","article-title":"Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program","volume":"24","author":"DiStefano","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"16","key":"10.1016\/j.vhri.2026.102132_bib38","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2014.13235","article-title":"Indication-specific pricing for cancer drugs","volume":"312","author":"Bach","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40258-019-00517-z","article-title":"Price models for multi-indication drugs: a systematic review","volume":"18","author":"Campillo-Artero","year":"2020","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib40","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jval.2021.11.1376","article-title":"The role of indication-based pricing in future pricing and reimbursement policies: a systematic review","volume":"25","author":"Preckler","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40273-018-0633-6","article-title":"The Australian managed entry scheme: are we getting it right?","volume":"36","author":"Tuffaha","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vhri.2026.102132_bib42","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40261-020-00972-w","article-title":"Performance-based risk-sharing arrangements (PBRSA): is it a solution to increase bang for the buck for pharmaceutical reimbursement strategy for our nation and around the world?","volume":"40","author":"Kim","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.vhri.2026.102132_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2021.100032","article-title":"Stakeholder views of managed entry agreements: a literature review of national studies","volume":"2","author":"Thanimalai","year":"2021","journal-title":"Health Policy Open"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5639\/gabij.2020.0901.003","article-title":"Pharmaceutical pricing policy in Saudi Arabia: findings and implications","volume":"9","author":"Alrasheedy","year":"2020","journal-title":"GaBI J"},{"key":"10.1016\/j.vhri.2026.102132_bib45","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.vhri.2018.03.004","article-title":"New drug reimbursement and pricing policy in Taiwan","volume":"15","author":"Chen","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.vhri.2018.08.007","article-title":"Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea","volume":"18","author":"Hasan","year":"2019","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40199-014-0080-7","article-title":"The evolution of Taiwan\u2019s National Health Insurance drug reimbursement scheme","volume":"23","author":"Hsu","year":"2015","journal-title":"Daru: J Fac Pharm Tehran Univ Med Sci"},{"issue":"16","key":"10.1016\/j.vhri.2026.102132_bib48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2019.2280","article-title":"Canada\u2019s amendment to patented drug price regulation: a prescription for global drug cost control?","volume":"321","author":"Humphries","year":"2019","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vhri.2026.102132_bib49","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healthpol.2020.07.017","article-title":"Pricing of in-patent pharmaceuticals in the Middle East and North Africa: is external reference pricing implemented optimally?","volume":"124","author":"Kanavos","year":"2020","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"10.1016\/j.vhri.2026.102132_bib50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev-publhealth-040119-094305","article-title":"Comparative approaches to drug pricing","volume":"41","author":"Kang","year":"2020","journal-title":"Annu Rev Public Health"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40258-017-0307-0","article-title":"Drug pricing in South Korea","volume":"15","author":"Kwon","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"issue":"S1","key":"10.1016\/j.vhri.2026.102132_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1017\/jme.2023.114","article-title":"How to price and to reimburse publicly funded medicines in Latin America? Lessons learned from Europe","volume":"51","author":"Leopold","year":"2023","journal-title":"J Law Med Ethics"},{"issue":"12","key":"10.1016\/j.vhri.2026.102132_bib53","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40273-022-01195-x","article-title":"Getting the price right: lessons for Medicare price negotiation from peer countries","volume":"40","author":"Rand","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004479-200404000-00008","article-title":"Working Group of the National Drug Utilisation Monitoring Centre (OsMed). Current national initiatives about drug policies and cost control in Europe: the Italy example","volume":"27","author":"Rocchi","year":"2004","journal-title":"J Ambul Care Manage"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0020731421996168","article-title":"Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for the United States","volume":"51","author":"Rodwin","year":"2021","journal-title":"Int J Health Serv"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14737167.2023.2292693","article-title":"The role of insurance policies in the drug pricing landscape","volume":"24","author":"Savova","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib57","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jval.2022.11.015","article-title":"Medicare drug price negotiation in the United States: implications and unanswered questions","volume":"26","author":"Sullivan","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/00207314211040948","article-title":"German pharmaceutical pricing: lessons for the United States","volume":"52","author":"Rodwin","year":"2022","journal-title":"Int J Health Serv"},{"key":"10.1016\/j.vhri.2026.102132_bib60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.vhri.2017.08.002","article-title":"Drug policy in the Czech Republic","volume":"13","author":"Skoup\u00e1","year":"2017","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11586640-000000000-00000","article-title":"Germany\u2019s decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules","volume":"9","author":"Gandjour","year":"2011","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1586\/erp.11.45","article-title":"The German method for setting ceiling prices for drugs: in some cases less data are required","volume":"11","author":"Gandjour","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/11592580-000000000-00000","article-title":"Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?","volume":"29","author":"Gerber","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2026.102132_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.vhri.2018.06.006","article-title":"Drug policy in Greece","volume":"16","author":"Yfantopoulos","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib65","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.vhri.2017.06.003","article-title":"Drug policy in Hungary","volume":"13","author":"Inotai","year":"2017","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10198-004-0225-6","article-title":"Pricing and reimbursement of drugs in Ireland","volume":"5","author":"Barry","year":"2004","journal-title":"Eur J Health Econ"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40258-020-00604-6","article-title":"Price reduction of anticancer drugs from 2007 to 2019 in South Korea: the impact of pharmaceutical cost-containment policies","volume":"19","author":"Kwon","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.vhri.2026.102132_bib68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vhri.2017.08.006","article-title":"Drug policy in Latvia","volume":"13","author":"Silins","year":"2017","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib69","series-title":"Pharmaceutical pricing and reimbursement policies in Mexico","author":"Moise","year":"2007"},{"issue":"6","key":"10.1016\/j.vhri.2026.102132_bib70","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1586\/14737167.2015.1048227","article-title":"Implications of external price referencing of pharmaceuticals in Middle East countries","volume":"15","author":"Kal\u00f3","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2026.102132_bib71","series-title":"Differences in costs of and access to pharmaceutical products in the EU","author":"Kanavos","year":"2018"},{"issue":"8","key":"10.1016\/j.vhri.2026.102132_bib72","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1634\/theoncologist.2016-0106","article-title":"Cancer drug pricing and reimbursement: lessons for the United States from around the world","volume":"21","author":"Goldstein","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.vhri.2026.102132_bib73","doi-asserted-by":"crossref","DOI":"10.3402\/jmahp.v4.30970","article-title":"Feasibility and attractiveness of indication value-based pricing in key EU countries","volume":"4","author":"Flume","year":"2016","journal-title":"J Mark Access Health Policy"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10198-002-0135-4","article-title":"Pricing and reimbursement of pharmaceuticals in Norway","volume":"3","author":"H\u00e5g\u00e5","year":"2002","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vhri.2026.102132_bib75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.vhri.2017.07.001","article-title":"Drug policy in Poland","volume":"13","author":"Jahnz-R\u00f3\u017cyk","year":"2017","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib76","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.vhri.2017.11.003","article-title":"Drug policy in Romania","volume":"16","author":"Radu","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib77","series-title":"OECD Health Working Papers No. 28","article-title":"Pharmaceutical Pricing and Reimbursement Policies in Sweden","author":"Moise","year":"2007"},{"key":"10.1016\/j.vhri.2026.102132_bib78","first-page":"S188","article-title":"Challenges and opportunities for improving the drug system in Thailand","volume":"29","author":"Thammatacharee","year":"2020","journal-title":"J Health Sci"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib79","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/cer-2017-0018","article-title":"Indication-specific pricing of pharmaceuticals in the US healthcare system","volume":"6","author":"Pearson","year":"2017","journal-title":"J Comp Eff Res"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib80","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jval.2020.11.009","article-title":"International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects","volume":"24","author":"Rand","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.102132_bib81","first-page":"1","article-title":"Pharmaceutical reference pricing: does it have a future in the U.S","volume":"2018","author":"Robinson","year":"2018","journal-title":"Issue Brief (Commonw Fund)"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.08.1499","article-title":"Impact of drug policy regulations on the consumption of antihypertensive drugs in Slovakia","volume":"17","author":"Psenkova","year":"2014","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib83","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/0020731419897580","article-title":"Pharmaceutical price and spending controls in France: lessons for the United States","volume":"50","author":"Rodwin","year":"2020","journal-title":"Int J Health Serv"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0020731421997094","article-title":"How the United Kingdom controls pharmaceutical prices and spending: learning from its experience","volume":"51","author":"Rodwin","year":"2021","journal-title":"Int J Health Serv"},{"issue":"6","key":"10.1016\/j.vhri.2026.102132_bib85","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14737167.2019.1592680","article-title":"Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria","volume":"19","author":"Vassileva","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.vhri.2026.102132_bib86","doi-asserted-by":"crossref","first-page":"E1083","DOI":"10.1001\/amajethics.2022.1083","article-title":"What should US policymakers learn from international drug pricing transparency strategies?","volume":"24","author":"Nagar","year":"2022","journal-title":"AMA J Ethics"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14737167.2024.2311302","article-title":"Drug pricing and transparency in Europe and the United States: what is it and how does it work?","volume":"24","author":"Simoens","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"10","key":"10.1016\/j.vhri.2026.102132_bib88","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.sapharm.2020.01.002","article-title":"Drug price transparency initiative: a scoping review","volume":"16","author":"Ahmad","year":"2020","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.vhri.2026.102132_bib89","series-title":"What Are the Implications of Policies Increasing Transparency of Prices Paid for Pharmaceuticals? A Primer for Understanding the Policy Perspective in Light of the Empirical Evidence","article-title":"European observatory policy briefs","author":"Webb","year":"2022"},{"key":"10.1016\/j.vhri.2026.102132_bib90","series-title":"The Consequences of Greater Net Price Transparency for Innovative Medicines in Europe: Searching for a Consensus","author":"Bentata","year":"2020"},{"key":"10.1016\/j.vhri.2026.102132_bib91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-8603-10-34","article-title":"Enhancing medicine price transparency through price information mechanisms","volume":"10","author":"Hinsch","year":"2014","journal-title":"Global Health"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-195007","article-title":"Affordability versus innovation: is compulsory licensing the solution?","volume":"30","author":"Pandey","year":"2019","journal-title":"Int J Risk Saf Med"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib93","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jval.2017.12.018","article-title":"Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.vhri.2026.102132_bib94","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ejca.2011.03.015","article-title":"The development of a value based pricing index for new drugs in metastatic colorectal cancer","volume":"47","author":"Dranitsaris","year":"2011","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib95","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40258-023-00860-2","article-title":"An optional delinked reward system: making pharmaceutical innovation work for everyone","volume":"22","author":"Hollis","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib96","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14737167.2023.2282680","article-title":"Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries","volume":"24","author":"Kal\u00f3","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"10.1016\/j.vhri.2026.102132_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113894","article-title":"The pricing of breakthrough drugs: theory and policy implications","volume":"9","author":"Levy","year":"2014","journal-title":"PLOS One"},{"issue":"11","key":"10.1016\/j.vhri.2026.102132_bib98","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/hec.4588","article-title":"Incentives to implement personalized medicine under second-best pricing","volume":"31","author":"Mougeot","year":"2022","journal-title":"Health Econ"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40273-023-01325-z","article-title":"A framework for the fair pricing of medicines","volume":"42","author":"Paulden","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10728-020-00394-x","article-title":"When are pharmaceuticals priced fairly? An alternative risk-sharing model for pharmaceutical pricing","volume":"28","author":"Balderrama","year":"2020","journal-title":"Health Care Anal"},{"key":"10.1016\/j.vhri.2026.102132_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2022.102613","article-title":"Paying for pharmaceuticals: uniform pricing versus two-part tariffs","volume":"83","author":"Brekke","year":"2022","journal-title":"J Health Econ"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib102","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10198-019-01032-7","article-title":"Is rate of return pricing a useful approach when value-based pricing is not appropriate?","volume":"20","author":"Drummond","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vhri.2026.102132_bib103","series-title":"Innovative Payment Models for High-cost Innovative Medicines","year":"2018"},{"issue":"4","key":"10.1016\/j.vhri.2026.102132_bib104","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10198-004-0237-2","article-title":"Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?","volume":"5","author":"Felder","year":"2004","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib105","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1056\/NEJMp1813728","article-title":"Universal medicine access through lump-sum remuneration\u2014Australia\u2019s approach to hepatitis C","volume":"380","author":"Moon","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib106","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/2159-8290.CD-21-1153","article-title":"Improving the affordability of anticancer medicines demands evidence-based policy solutions","volume":"12","author":"Franzen","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.vhri.2026.102132_bib107","series-title":"WHO Guideline on Country Pharmaceutical Pricing Policies","author":"Cameron","year":"2015"},{"key":"10.1016\/j.vhri.2026.102132_bib108","series-title":"WHO guideline on country pharmaceutical pricing policies","year":"2020"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib109","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1056\/NEJMsa1700087","article-title":"Association of reference pricing with drug selection and spending","volume":"377","author":"Robinson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2026.102132_bib110","series-title":"Pharmaceutical Pricing Policies in a Global Market","year":"2008"},{"key":"10.1016\/j.vhri.2026.102132_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-084839","article-title":"Collective international action to increase access to costly drugs: pooled procurement and equity based tiered pricing","volume":"391","author":"Kal\u00f3","year":"2025","journal-title":"BMJ"},{"issue":"S1","key":"10.1016\/j.vhri.2026.102132_bib112","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10551-008-9682-7","article-title":"Where strategy and ethics converge: pharmaceutical industry pricing policy for Medicare part D beneficiaries","volume":"84","author":"Balotsky","year":"2009","journal-title":"J Bus Ethics"},{"issue":"8","key":"10.1016\/j.vhri.2026.102132_bib113","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1377\/hlthaff.2010.0317","article-title":"The level of income appears to have no consistent bearing on pharmaceutical prices across countries","volume":"30","author":"Morel","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vhri.2026.102132_bib114","series-title":"Differential Pricing for Pharmaceuticals Review of current knowledge, new findings and ideas for action","author":"Yadav","year":"2010"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/03085147.2024.2346037","article-title":"The temporalities of prices: \u201cValue-based pricing\u201d in pharmaceutical markets","volume":"53","author":"Doganova","year":"2024","journal-title":"Econ Soc"},{"key":"10.1016\/j.vhri.2026.102132_bib116","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3389\/fpubh.2018.00328","article-title":"Barriers for access to new medicines: searching for the balance between rising costs and limited budgets","volume":"6","author":"Godman","year":"2018","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib117","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40258-018-0437-z","article-title":"Effectiveness of national pricing policies for patent-protected pharmaceuticals in the OECD: a systematic literature review","volume":"17","author":"Wettstein","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib118","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40273-017-0567-4","article-title":"Value-based pricing: l\u2019enfant terrible?","volume":"36","author":"Garner","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLOS Med"},{"key":"10.1016\/j.vhri.2026.102132_bib120","series-title":"Global oncology trend report","article-title":"Developments in cancer treatments, market dynamics, patient access and value","author":"Aitken","year":"2015"},{"key":"10.1016\/j.vhri.2026.102132_bib121","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcpo.2016.09.003","article-title":"Value assessment in precision cancer medicine","volume":"11","author":"Towse","year":"2017","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.vhri.2026.102132_bib122","series-title":"AMCP Guide to Pharmaceutical Payment Methods. Version 3.0","year":"2013"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2016.03.056","article-title":"Multi-indication pricing: pros, cons, and its applicability to the United Kingdom","volume":"19","author":"Mestre-Ferrandiz","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.102132_bib124","series-title":"Opinion on Innovative payment models for high-cost innovative medicines","author":"De Maeseneer","year":"2018"},{"issue":"12","key":"10.1016\/j.vhri.2026.102132_bib125","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40273-017-0559-4","article-title":"The implementation of managed entry agreements in Central and Eastern Europe: findings and implications","volume":"35","author":"Ferrario","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.vhri.2026.102132_bib126","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.sapharm.2020.06.007","article-title":"Drug price transparency initiative: the need for a broader view","volume":"16","author":"Leite","year":"2020","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.vhri.2026.102132_bib127","series-title":"Exploring the consequences of greater price transparency on the dynamics of pharmaceutical markets","author":"Barrenho","year":"2022"},{"key":"10.1016\/j.vhri.2026.102132_bib128","series-title":"The Consequences of Greater Net Price Transparency for Innovative Medicines in Europe: Searching for a Consensus","author":"Pistollato","year":"2020"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib129","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1017\/S0266462322000514","article-title":"Disinvestment in healthcare: a scoping review of systematic reviews","volume":"38","author":"Kamaruzaman","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S0266462312000372","article-title":"Using health technology assessment to support optimal use of technologies in current practice: the challenge of \u201cdisinvestment\u201d","volume":"28","author":"Henshall","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vhri.2026.102132_bib131","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5688\/aj710359","article-title":"Pharmaceutical economics and policy","volume":"71","author":"Cline","year":"2007","journal-title":"Am J Pharm Educ"},{"key":"10.1016\/j.vhri.2026.102132_bib132","series-title":"Pharmaceutical Economics and Policy Perspectives, Promises, and Problems","author":"Schweitzer","year":"2018"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib133","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JGO.2016.005363","article-title":"Compulsory licenses for cancer drugs: does circumventing patent rights improve access to oncology medications?","volume":"2","author":"Bognar","year":"2016","journal-title":"J Glob Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib134","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12913-017-2304-2","article-title":"Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status","volume":"17","author":"Maniadakis","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib135","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1377\/hlthaff.2018.05207","article-title":"Using external reference pricing in Medicare part D To reduce drug price differentials with other countries","volume":"38","author":"Kang","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vhri.2026.102132_bib136","series-title":"Compulsory Licensing: Practical Experiences and Ways Forward","first-page":"61","article-title":"Compulsory licences: law and practice in Thailand","author":"Kuanpoth","year":"2015"},{"key":"10.1016\/j.vhri.2026.102132_bib137","author":"Vawda"},{"key":"10.1016\/j.vhri.2026.102132_bib138","series-title":"Value in Pharmaceutical Pricing","author":"Paris","year":"2013"},{"key":"10.1016\/j.vhri.2026.102132_bib139","series-title":"OECD Health Working Paper No. 115. Performance-based managed entry agreements for new medicines in OECD countries and EU member states","article-title":"Health working papers","year":"2019"},{"key":"10.1016\/j.vhri.2026.102132_bib140","series-title":"PPRI Pharma Brief: Austria 2023. Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series","author":"Vogler","year":"2024"},{"key":"10.1016\/j.vhri.2026.102132_bib141","author":"Wadmann"},{"key":"10.1016\/j.vhri.2026.102132_bib142","first-page":"25","article-title":"Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland","volume":"20","author":"Kwong","year":"2014","journal-title":"Eurohealth"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2165\/00019053-200826010-00002","article-title":"The last decade of Italian pharmaceutical policy: instability or consolidation?","volume":"26","author":"Fattore","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib144","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.healthpol.2004.02.012","article-title":"Pharmaceutical policy in Italy: towards a structural change?","volume":"72","author":"Ghislandi","year":"2005","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"10.1016\/j.vhri.2026.102132_bib145","series-title":"Payer policies to support innovation and access to medicines in the WHO European region","author":"Vogler","year":"2022"},{"key":"10.1016\/j.vhri.2026.102132_bib150","series-title":"Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium","author":"Ferrario","year":"2013"},{"key":"10.1016\/j.vhri.2026.102132_bib151","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vhri.2017.07.002","article-title":"Drug policy in Slovakia","volume":"13","author":"Bucek Psenkova","year":"2017","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.vhri.2026.102132_bib153","series-title":"Making Medicines in Africa","first-page":"203","article-title":"Policies to control prices of medicines: does the South African experience have lessons for other African countries?","author":"Ngozwana","year":"2016"},{"issue":"1","key":"10.1016\/j.vhri.2026.102132_bib154","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11096-018-0758-x","article-title":"The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa","volume":"41","author":"de Jager","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.vhri.2026.102132_bib156","article-title":"Patients\u2019 access to drugs with rebates in Switzerland\u2014Empirical analysis and policy implications for drug pricing in Europe","volume":"3","author":"Carl","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vhri.2026.102132_bib157","series-title":"Addressing challenges in access to oncology medicines. Analytical Report","year":"2020"},{"key":"10.1016\/j.vhri.2026.102132_bib158","series-title":"Introduction to Market Access for Pharmaceuticals","first-page":"74","author":"Toumi","year":"2017"},{"issue":"11","key":"10.1016\/j.vhri.2026.102132_bib159","article-title":"Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System","volume":"32","author":"Scopel","year":"2016","journal-title":"Cad Sa\u00fade Publ"},{"key":"10.1016\/j.vhri.2026.102132_bib161","first-page":"1","article-title":"Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand","volume":"7","author":"Danzon","year":"2004","journal-title":"Front Health Policy Res"},{"issue":"3","key":"10.1016\/j.vhri.2026.102132_bib162","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007021","article-title":"Health technology assessment in Switzerland: a descriptive analysis of \u201cCoverage with Evidence Development\u201d decisions from 1996 to 2013","volume":"5","author":"Br\u00fcgger","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.vhri.2026.102132_bib163","article-title":"Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer\u2019s disease: patient outcomes, healthcare costs, and drug development","volume":"20","author":"Brockmann","year":"2023","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"10.1016\/j.vhri.2026.102132_bib165","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/cid\/ciu012","article-title":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries","volume":"58","author":"Hill","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vhri.2026.102132_bib166","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vhri.2026.102132_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.vhri.2026.102132_bib168","series-title":"Promoting price transparency: WHO guideline on country pharmaceutical pricing policies","year":"2021"},{"issue":"2","key":"10.1016\/j.vhri.2026.102132_bib169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40273-019-00877-3","article-title":"Talkin\u2019 about a resolution: issues in the push for greater transparency of medicine prices","volume":"38","author":"Shaw","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vhri.2026.102132_bib170","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1377\/hlthaff.26.5.1384","article-title":"Would greater transparency and uniformity of health care prices benefit poor patients?","volume":"26","author":"Kyle","year":"2007","journal-title":"Health Aff (Millwood)"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926005479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:25:17Z","timestamp":1791602717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926005479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,3]]},"references-count":160,"alternative-id":["S2212109926005479"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102132","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2027,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Strategies Can Payers Use to Negotiate Medicine Prices Globally? Insights and Lessons for Low-Income Countries from a Scoping Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.102132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"102132"}}